- Home
- /
- history-renew1
About Us
History
Established in 2006, Genolution Inc. has been providing solutions toward a better life by focusing on the fields of molecular diagnostics and RNAi. Welcome to Genolution.
2024 ~ Present
World’s First Commercialization of RNAi & Strengthening of Future Core IP Portfolio
Strengthening growth momentum through liquid biopsy and discovery of disease biomarkers
2026
‘Honeyguard-R’ designated as an Innovative Product by the Public Procurement Service (PPS)
Registered a patent for RNA pest control targeting specific genes of the pine wood nematode
2025
Expanded patent portfolio for RNAi-based eco-friendly crop protection products
Filed a patent for a next-generation methylation-based biomarker for high-risk cervical cancer prediction
2024
Obtained product approval for ‘Honeyguard-R’, the world’s first RNAi-based veterinary medicine
Built a global production infrastructure with the completion of the 2nd Songdo Headquarters
2021 ~ 2023
Expansion of Global R&D Network, Platform Diversification & Transition to New Businesses
Strengthening global competitiveness through the opening of Magok R&D Hub and large-scale export achievements
2023
Launched subsidiary Bienble Biotech (Expanding business into the beauty sector)
‘NX-Duo’, an automated nucleic acid extraction system, designated as an Innovative Product by the Ministry of SMEs and Startups (MSS)
2022
Selected as a consortium partner for the EU ‘Horizon Europe’ program
Approved by the Ministry of Food and Drug Safety (MFDS) for the cfDNA extraction kit for liquid biopsy
2021
Constructed the Magok R&D Center and Corporate R&D Institute
Simultaneously awarded the ‘Gold Tower Order of Industrial Service Merit’ and the ’70 Million Dollar Export Tower’ by the Korean Government
2016 ~ 2020
Securing Global Quality Competitiveness & Relisting on the KOSDAQ Market
Accelerating entry into the global in vitro diagnostics (IVD) market utilizing US FDA and China CFDA registrations as a stepping stone
2020
Relisted on the KOSDAQ market from KONEX
2017
Proprietary development of automated nucleic acid extraction instruments and dedicated reagents
2016
Registered the automated nucleic acid extraction platform with the US FDA and China CFDA2011 ~ 2015
Internalization of Core Molecular Diagnostic Technologies & Establishing Business Foundations
Accelerating the in vitro diagnostics (IVD) business based on the proprietary development of automated nucleic acid extraction platforms
2015
Listed on the KONEX market
2012
Proprietary development of automated nucleic acid extraction instruments and dedicated reagents
2006 ~ 2011
Securing Core RNAi Technologies & Establishing R&D Foundations
Laying the groundwork for innovative growth through the development of proprietary RNA synthesis technology
2008
Developed a proprietary RNA synthesis method and secured initial core proprietary technologies
2007
Received official certification for the Corporate R&D Institute
2006
Incorporated Genolution Inc.
